{"id":9715,"date":"2026-04-08T16:05:41","date_gmt":"2026-04-08T16:05:41","guid":{"rendered":"https:\/\/stoxpo.com\/?p=9715"},"modified":"2026-04-08T16:05:41","modified_gmt":"2026-04-08T16:05:41","slug":"viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/","title":{"rendered":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><em>Late-stage pipeline progress and market momentum position the biotech as a key emerging player<\/em><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Viking Therapeutics (VKTX) is entering a pivotal phase in 2026, with investors closely watching its progress in the highly competitive obesity drug market. The clinical-stage biotech company has gained significant attention due to its lead candidate, VK2735, a dual GLP-1 and GIP receptor agonist designed to compete with blockbuster treatments from industry leaders.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company\u2019s biggest catalyst remains its ongoing Phase 3 clinical trials for VK2735. Enrollment for the VANQUISH-1 study has already been completed ahead of schedule, with more than 4,600 patients enrolled, while the VANQUISH-2 trial is nearing completion. These milestones mark an important step toward potential regulatory approval and commercialization, with key data expected later in 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Earlier-stage results have been encouraging. In Phase 2 trials, VK2735 demonstrated weight loss of up to 14.7% over 13 weeks without a plateau, positioning it as a strong contender in a market projected to exceed $100 billion in the coming years. The company is also advancing both injectable and oral formulations, with the oral version expected to enter Phase 3 trials in the second half of 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Beyond its flagship obesity program, Viking continues to build a broader pipeline targeting metabolic and endocrine disorders, supported by a solid balance sheet and disciplined capital management. This financial strength is critical as the company navigates the high costs associated with late-stage clinical development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investor sentiment remains cautiously optimistic. While competition from major pharmaceutical companies like Eli Lilly and Novo Nordisk is intense, Viking\u2019s dual-mechanism approach and rapid trial progress have positioned it as a credible challenger. Additionally, growing industry interest in obesity treatments has fueled speculation around potential partnerships or acquisition opportunities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As Viking Therapeutics advances toward key clinical readouts, 2026 stands as a defining year. Success in its Phase 3 trials could transform the company from a development-stage biotech into a major player in one of the fastest-growing segments in healthcare.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/global-markets-surge-in-relief-rally-as-geopolitical-tensions-ease\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Global Markets Surge in Relief Rally as Geopolitical Tensions Ease<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Late-stage pipeline progress and market momentum position the biotech as a key emerging player Viking Therapeutics (VKTX) is entering a pivotal phase in 2026, with investors closely watching its progress in the highly competitive obesity drug market. The clinical-stage biotech company has gained significant attention due to its lead candidate, VK2735, a dual GLP-1 and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1430,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,361],"tags":[421,416,418,676,417,793],"coauthors":[454],"class_list":["post-9715","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-large-cap","tag-growth","tag-movers","tag-news","tag-spy","tag-stock-market","tag-vktx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Late-stage pipeline progress and market momentum position the biotech as a key emerging player Viking Therapeutics (VKTX) is entering a pivotal phase in 2026, with investors closely watching its progress in the highly competitive obesity drug market. The clinical-stage biotech company has gained significant attention due to its lead candidate, VK2735, a dual GLP-1 and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T16:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1706\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race\",\"datePublished\":\"2026-04-08T16:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/\"},\"wordCount\":339,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"keywords\":[\"Growth\",\"Movers\",\"News\",\"SPY\",\"Stock Market\",\"VKTX\"],\"articleSection\":[\"Biotechnology\",\"Large-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/\",\"name\":\"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"datePublished\":\"2026-04-08T16:05:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-polina-tankilevitch-3735709-scaled.jpg\",\"width\":2560,\"height\":1706,\"caption\":\"chemistry\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/04\\\/08\\\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race - Stoxpo","og_description":"Late-stage pipeline progress and market momentum position the biotech as a key emerging player Viking Therapeutics (VKTX) is entering a pivotal phase in 2026, with investors closely watching its progress in the highly competitive obesity drug market. The clinical-stage biotech company has gained significant attention due to its lead candidate, VK2735, a dual GLP-1 and [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/","og_site_name":"Stoxpo","article_published_time":"2026-04-08T16:05:41+00:00","og_image":[{"width":2560,"height":1706,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race","datePublished":"2026-04-08T16:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/"},"wordCount":339,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","keywords":["Growth","Movers","News","SPY","Stock Market","VKTX"],"articleSection":["Biotechnology","Large-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/","url":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/","name":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","datePublished":"2026-04-08T16:05:41+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-polina-tankilevitch-3735709-scaled.jpg","width":2560,"height":1706,"caption":"chemistry"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2026\/04\/08\/viking-therapeutics-a-high-stakes-year-in-the-obesity-drug-race\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics: A High-Stakes Year in the Obesity Drug Race"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=9715"}],"version-history":[{"count":2,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9715\/revisions"}],"predecessor-version":[{"id":9717,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9715\/revisions\/9717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1430"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=9715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=9715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=9715"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=9715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}